Get startedLog in
    Picture of Egetis Therapeutics AB (publ) logo

    EGTX — Egetis Therapeutics AB (publ) News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapMomentum Trap
    All News

    Brief: Egetis Receives Positive EMA Opinion For Orphan Designation Of Emcitate

    Picture of Egetis Therapeutics AB (publ) logoEgetis Therapeutics AB (publ)
    24/03/2022 07:06
    March 24 (Reuters) - Egetis Therapeutics AB (publ)
 EGTX.ST :
    * EGETIS RECEIVES POSITIVE EMA OPINION FOR ORPHAN
DESIGNATION OF
EMCITATE FOR TREATMENT OF RESISTANCE TO THYROID HORMONE TYPE
BETA (RTH-Β)

Source text for Eikon:  ID:nMFN56ftfq 
Further company coverage:  EGTX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on Egetis Therapeutics AB (publ)

    See all news